Where does OncoSec Medical Incorporated rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OncoSec Medical Incorporated ranks #32,739 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OncoSec Medical Incorporated hold?

OncoSec Medical Incorporated holds 8 US utility patents granted between 2015 and 2023, spanning 12 technology areas.

What is OncoSec Medical Incorporated's Innovation Score?

OncoSec Medical Incorporated has an Innovation Score of 36.5 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does OncoSec Medical Incorporated focus on?

OncoSec Medical Incorporated's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 7 patents, ranking #515 of 1,943 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is OncoSec Medical Incorporated's patent grant rate increasing or decreasing?

OncoSec Medical Incorporated's recent grant velocity is +67% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for OncoSec Medical Incorporated's patents?

OncoSec Medical Incorporated's patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OncoSec Medical Incorporated patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

OncoSec Medical Incorporated

USPTO PatentsView assignee record - 8 granted patents across 12 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oncosec ranks #32,739 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 12 technology areas.

#32,739
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.5/100): 16.8
avg claims per patent: +67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32739 · US Corporation #32,739 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,739/49,997
PHOTO-FINISH Omnicharge
CPC-FOCUS A61N · 12 areas
INNOV-THIN 36.5/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Omnicharge, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oncosec’s 36.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (21%) Velocity 6.7 pts (18%) Breadth 12.2 pts (33%) Claim depth 10.1 pts (28%)

Qualcomm Incorporated · highest

85
OncoSec Medical… · this assignee

37
3D Lighting… · lowest

7

What this shows Oncosec's Innovation Score is 36.5/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oncosec?

Each dot is one of Oncosec’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncosec’s own 16.8 claims/patent is at or below the 17.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Oncosec vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oncosec's grants concentrate

OncoSec Medical Incorporated is a focused PatentsView assignee: 12 CPC subclasses with 87.5% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2019. By volume, Oncosec sits between Omnicharge, Inc. and Opal Labs Inc..

Oncosec's three-year grant acceleration

OncoSec Medical Incorporated shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Omnicharge

8
Omnis Advanced

8
Onboard Security

8
Oncam Global

8
Onduline

8
Oneblade

8
Onward Multi-

8
Opal Labs

8
Oncosec Medical I… ◀

8

What this shows OncoSec holds 8 patents at rank #32,744, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OncoSec

By rank, the assignees closest to #32,744 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in OncoSec's primary technology class.

Oncosec's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

OncoSec Medical Incorporated patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	25.0%
2019	1	12.5%
2021	2	25.0%
2022	1	12.5%
2023	2	25.0%

Which technologies does OncoSec Medical Incorporated patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C07K - Peptides 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

A61B - DIAGNOSIS; SURGERY; Identification 1

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 1

H02H - Emergency Protective Circuit Arrangements 1

H03K - Pulse Technique 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OncoSec Medical Incorporated's patent record in context - here's where to go next.

OncoSec Medical Incorporated's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 87.5% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #32,739 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OncoSec Medical Incorporated against Omnicharge, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.